Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...
CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc. (NASDAQ:BEAM) announced new efficacy and safety findings from its BEACON Phase 1/2 ...
Seventy-five percent reached the primary study end point of immunosuppression-free for more than 2 years. HealthDay News — Kidney transplant recipients receiving the investigational cellular product ...
A domestically developed gene-editing therapy has successfully treated patients with beta-thalassemia, allowing them to live ...
SINGAPORE, July 7, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced ...
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
Fifteen of 20 HLA-matched living donor recipients achieved the primary end point of being immunosuppression-free for more than two years. (HealthDay News) — Kidney transplant recipients receiving the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results